Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus EC/EP for First-line SCLC
NCT03890055Phase 4Unknown
- Sponsor
- Chifeng Municipal Hospital
- Start
- Apr 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of anlotinib in small cell lung cancer (SCLC), sponsored by Chifeng Municipal Hospital. Primary endpoint: Progression-Free Survival at 9 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03890055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890055.